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Abstract
Background: Oral mucosal melanoma (OMM) is a clinically rare disease with poor prognosis. Various treatment
methods have been investigated with the aim of improving the prognosis. This study aimed to analyze the data of
a single institution in the management of OMM.
Methods: A total of 78 consecutive OMM patients were included in this retrospective study. The intraoral lesion
was treated either by cryotherapy, surgery or both; the neck was treated by neck dissection or observation; post-
operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin was performed in some
patients. The Kaplan-Meier method was used for statistical analysis.
Results: Among the 78 patients, there were 50 males and 28 females with an average age of 53.8 years (ranging
from 27 to 85 years). The most common sites of OMM were the hard palate and gingiva. The main cause of death
in OMM was distant metastasis. No significant difference was found between the intraoral/cervical lesion
recurrence/post-operative distant metastasis and the intraoral lesion site/biopsy method/treatment method. The
metastasis rate of cervical lymph node was high in the OMM patients, even in the patients with clinically negative
necks. Cervical lesion recurrence was correlated with N stage and intraoral lesion recurrence. The survival period
was longer in the patients with T3 staging, clinical stage III disease, with post-operative chemotherapy and without
post-operative distant metastasis when compared to those patients with T4a staging, clinical stage IV disease,
without post-operative chemotherapy and with post-operative distant metastasis.
Conclusions: Radical surgery including wide intraoral resection and neck dissection is recommended for OMM
patients. Post-operative chemotherapy may also be beneficial for both primary and recurrent OMM patients.
Background
Oral mucosal melanoma (OMM) is a clinically rare
malignancy arising from melanocytes within the mucosal
epithelia of oral cavity. Its etiology and pathogenesis are
poorly understood. OMM accounts for 0.2-8% of all mel-
anomas and 0.26-0.5% of oral malignancies [1-4], and
occurs with a higher incidence in adults aged sixties,
without any gender preference. The most common sites
of OMM are the hard palate and maxillary gingiva. The
prognosis of OMM is poor with a very low 5-year survi-
val rate (about 10-25% or even lower) [1-4]. Clinically,
OMM may present as a macular or nodular lesion with
its surface color ranging from brown, grey, black and
white to purple and red shade or even depigmented
[2,3,5]. Satellite lesions frequently surround the initial
tumor. Cervical lymph node metastasis (CLNM) and dis-
tant metastasis often occur in OMM patients with distant
metastasis being the main cause of death [6]. As such,
early diagnosis and treatment is the key in improving the
prognosis. Surgery has been t h em a i n s t a yt r e a t m e n tf o r
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recommended. Other treatment modalities have included
chemotherapy [dimethyl triazeno imidazole carboxamide
(DTIC), platinum analogs, vincristine, and nimustine
hydrochloride], radiotherapy, vaccine-based therapy, and
immunotherapy (interleukin-2 and interferon) [7-11].
Because of the poor prognosis in advanced disease, pallia-
tive care may be the only option in such cases. Although
much effort has been directed towards modifying treat-
ment protocols so as to improve the prognosis of OMM
patients, some treatment issues are still under debate.
These include the efficacy of cryotherapy in controlling
the intraoral lesion, the need for neck dissection and the
decision of which post-operative chemotherapy protocol
to implement. Recently, mucosal melanoma of the head
and neck has been added to the new AJCC-TMN classifi-
cation (Additional file 1) [12]. In contrast to the previous
TMN classification, under this new classification, tumor
size T1 and T2 and clinical stage I and II are omitted
because of the aggressiveness of this disease. Regarding
tumor size, for T3 lesions, they are located in the epithe-
lium or submucosa, just as in mucosal disease. For T4a
lesions, they are located in the deep soft tissue, cartilage,
bone, or overlying skin. For T4b lesions, they have
invaded the brain, dura, skull base, lower cranial nerves,
masticator space, carotid artery, prevertebral space, med-
iastinal structures, cartilage, skeletal muscle, or bone.
Regarding stage grouping, stage III is T3N0M0, stage
IVA is T4aN0M0 and T3-4aN1M0, stage IVB is
T4bAnyN and stage IVC is AnyTAnyNM1. In the cur-
rent study, we presented 78 consecutive OMM cases (64
primary OMMs and 14 recurrent OMMs) and have also
discussed the various aspects of intraoral lesion manage-
ment, neck management and post-operative chemother-
apy with the protocol of DTIC and cisplatin (also known
as cis-diaminedichloroplatinum, CDDP).
Methods
From January 2004 to January 2010, 78 consecutive
OMM patients, including 64 primary OMMs and 14
recurrent OMMs, were retrospectively reviewed with
their clinical data (Additional file 2). These patients
were treated at the Department of Oral and Maxillofa-
cial Surgery, Ninth People’s Hospital, School of Medi-
cine, Shanghai Jiao Tong University. From the clinical
data, routine clinical examination was performed in all
patients. In addition, computerized tomography (CT) of
the craniomaxillofacial region, neck, and lung was also
performed.
99Tc emission computerized tomography of
entire body was performed in patients in whom bony
distant metastasis was suspected. PET-CT was initially
recommended in such cases, but the majority of these
patients refused this due to economic reasons. After
signing the informed consent forms, all patients with
primary or recurrent OMMs received pre-operative inci-
sional or excisional biopsy of the intraoral lesion at
room temperature or pre-operative incisional biopsy
during cryotherapy or intra-operative frozen section for
pathological diagnosis.
For intraoral lesions, the pre-operative incisional or
excisional biopsy was performed under local anesthesia
with 1% lidocaine (Lidocaine Hydrochloride Injection,
Shanghai Fuda Pharmaceutical Ltd, Shanghai, China).
Routine pathological examination was performed using
hematoxylin and eosin (HE) staining; if the diagnosis
was unclear, immunohistochemical examination was
performed using the S-100, Vimentin, HMB45 and Mel-
anA antibodies, which would show positivity for mela-
noma. The incisional biopsy during cryotherapy or
intra-operative frozen section was performed under
local anesthesia with 1% lidocaine; frozen pathological
examination was performed using HE staining. If the
diagnosis was unclear, further specimens were taken
until a definite pathological diagnosis was obtained. As
part of the neck examination, if CT scan showed
CLNM, fine needle aspiration cytology (FNAC) exami-
nation was not suggested; if in clinically suspicious
CLNM cases whereby CLNM could not be verified by
CT scan, FNAC examination was performed on the sus-
picious lymph node.
For patients with clinical stage III disease, cryotherapy
was initially suggested for the treatment of intraoral
lesions. However, when the lesion was large or in cases
whereby bony exposure occurred after cryotherapy, sur-
gical resection was performed. Surgery was also indi-
cated if patients had refused cryotherapy. For patients
with clinical stage IVA disease, cryotherapy and surgical
resection were both performed. In such cases, the muco-
sal or submucosal lesion was treated by cryotherapy
while the invaded deep structures were removed by sur-
gery. Similarly, surgery was performed if patients refused
cryotherapy. For patients with clinical stage IVB and
IVC disease, chemotherapy with/without radiotherapy
was recommended. Post-operative chemotherapy was
recommended in patients with positive surgical margins.
Cryotherapy was performed under local anesthesia
with 1% lidocaine. A special cryospray unit (HX17-
YDQ-500, Beijing Western Vision Technology Co., Ltd.,
Beijing, China) was used to spray liquid nitrogen on to
the oral mucosa to destroy the involved lesion of oral
mucosa as well as 0.5 cm marginal mucosa. If the
intraoral lesion could not be confidently controlled, sur-
gical operation was performed. In cases whereby safety
margins could not be achieved due to functional and
aesthetic limitations, intra-operative cryotherapy was
performed at these resection margins.
Surgical resection was performed in the majority of
OMMs patients. For intraoral lesions, an extended
Yang et al. BMC Cancer 2010, 10:623
http://www.biomedcentral.com/1471-2407/10/623
Page 2 of 9resection with a 2 cm safety margin was performed. For
lesions of the hard palate and maxillary gingiva,
extended resection with subtotal maxillectomy for T3
lesions and total maxillectomy with or without preserva-
tion of the orbital floor for T4a lesions was preformed.
For lesions of the mandibular gingiva, extended resec-
tion with marginal mandibulectomy for T3 lesions and
segmental mandibulectomy for T4a lesions was per-
formed. Radical neck dissection was planned in patients
with clinically positive CLNM while functional neck dis-
section was planned in patients with clinically negative
CLNM.
The following chemotherapy protocol of DTIC
(Dacarbazine Injection, Nanjing Pharmaceutical Factory
Co. Ltd., Jiangsu, China) and CDDP (cisplatin Injection,
Qilu Pharmaceutical Co. Ltd., Shandong, China) was
used: 80 mg/m
2 of CDDP on the first day, 250 mg/m
2
of DTIC from the first day to the fifth day. After two
weeks, patients received a second cycle of chemotherapy
(21 days of each cycle). Two to four cycles were recom-
mended; if response was stable disease, more cycles
were used; if patients could not tolerate the complica-
tions of chemotherapy, chemotherapy was stopped.
For patients with recurrent OMMs, extended resection
with post-operative chemotherapy was performed. The
chemotherapy protocol was the same as previously
described. Post-operative radiotherapy was recom-
mended for patients whose disease could not be con-
trolled by surgery and post-operative chemotherapy.
Follow-up reviews were carried out for all patients
after the initial treatment: every 2-4 months during the
first year, every 4-6 moths during the second year, and
then twice a year. Besides physical examinations, CT
scans of the craniomaxillofacial region, neck, and lung
and
99Tc emission computerized tomography of entire
body were performed every half a year. PET-CT was
performed if there was suspicion of distant metastasis to
lung, brain or bones. If there was a suspicion of a recur-
rent intraoral lesion, incisional or excisional biopsy was
performed. All data was analyzed using SPSS 13.0 for
Windows (SPSS Inc., USA), and the survival analysis
was performed using the Kaplan-Meier method. Statisti-
cally significance was set at P < 0.05.
Results
The clinical records of 78 patients were analyzed and
were presented in Table 1. The sample consisted of 50
males and 28 females with an average age of 53.8 years
(ranging from 27 to 85 years). With regards to the site
of lesion, 35 lesions originated from the hard palatal
mucosa, 20 lesions from the maxillary gingival mucosa,
16 lesions from the mandibular gingival mucosa, three
lesions from the buccal mucosa, three lesions from the
lip mucosa and one lesion from the mucosa of the floor
of mouth. From the sample of 78 patients, 64 patients
presented with primary OMMs while 14 patients pre-
sented with recurrent OMMs. The disease course of pri-
mary OMM patients ranged from 1 to 48 months with
a mean of 6.6 months, while that of recurrent OMM
patients ranged from 1 to 36 months with a mean of 2.8
months. The majority of patients presented with local
Table 1 Clinical parameters of 78 patients with oral
mucosal melanoma
Clinical parameters Number of patients (%)
Primary patients 64
Sex
Male 41 (64.1)
Female 23 (35.9)
Age (years old)
< 30 1 (1.6)
30-39 10 (15.6)
40-49 16 (25)
50-59 27 (42.2)
60-69 11 (17.2)
70-79 11 (17.2)
≥ 80 2 (3.1)
Intraoral site
Hard palate 28 (43.8)
Maxillary gingiva 15 (23.4)
Mandibular gingiva 14 (21.9)
Buccal mucosa 3 (4.7)
Lip 3 (4.7)
Floor of mouth 1 (1.6)
T stage
T3 53 (82.8)
T4a 11 (17.2)
N stage
cN0 38 (59.4)
cN1 26 (40.6)
pN- 25 (39)
pN0 3 (4.7)
pN1 36 (56.3)
M stage
M0 62 (96.9)
M1 2 (3.1)
Clinical stage
III 22 (34.4)
IVA 40 (62.5)
IVC 2 (3.1)
Recurrent patients 14
Sex
Male 9 (64.3)
Female 5 (35.7)
Type of recurrence
Intraoral recurrence 5 (35.7)
Intraoral and neck recurrence 9 (64.3)
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purple or red shades) with only three patients presenting
with local swelling without surface pigmentation. Other
surface characteristics of OMM included a smooth sur-
face or ulceration with bleeding and pain and occasional
tooth loosening. 35 patients (26 patients with primary
OMMs and 9 patients with recurrent OMMs) presented
with enlarged cervical lymph nodes.
Primary OMM
According to the AJCC-TNM classification for the
mucosal melanoma of the head and neck [12], among
the 64 patients with primary OMMs in our study, per-
taining to T staging, 53 patients presented with stage T3
while 11 patients presented with stage T4a. With regard
to clinical N staging, 38 patients presented with stage
cN0 with 26 patients presenting with stage cN1. For dis-
tant metastasis M staging, 62 patients presented with
stage M0 with the remaining two patients presenting
with stage M1. Among the 39 patients who received
neck dissection, three patients were staged pN0 while
36 patients were staged pN1. As such, with regards to
stage grouping, 22 patients were at clinical stage III,
40 patients were at clinical stage IVA and two patients
were at clinical stage IVC. During the follow-up period
f r o m3t o6 7m o n t h s( w i t ham e a no f3 5 . 5m o n t h s ) ,
12 patients were lost. The overall survival rate of
the patients with primary OMMs was 61.5%, and the 1-,
2-, 3- and 5-year survival rate was 58.3%(28/48), 53.1%
(17/32), 35.0%(7/20) and 36.4%(4/11), respectively. The
local lesion recurrence rate was 30.7%, while the recur-
rence rate of late CLNM was 15.4%. Our data showed
that there was no significant difference in survival rate
between the different distributions of sex, age, course of
disease and primary lesion site.
Local lesion management
Three types of intraoral lesion treatment were per-
formed and this included cryotherapy only (36 cases),
surgery only (11 cases), cryotherapy and surgery
(17 cases), respectively. Among the 52 patients with
complete follow up data, no significant relationship
between the intraoral lesion recurrence and the lesion
site (P = 0.39), T stage (P = 0.49), biopsy method (P =
0.18), intraoral lesion treatment method (P = 0.50), or
post-operative chemotherapy (P = 0.23) was found.
However, the intraoral lesion recurrence rate was some-
what higher in the patients with cryotherapy than that
in the patients without cryotherapy (Table 2). The mean
survival period of patients with T3 staging was 48.4 ±
4.2 (95% CI: 40.2-56.6) months, which was significantly
longer (Log Rank = 20.315, P < 0.001) than that of
patients with T4a staging [11.3 ± 1.4 (95% CI: 8.6-14.0)
months]. There was no significant difference in survival
rates among patients with different intraoral lesion
treatment methods (Log Rank = 1.561, df = 2, P = 0.46).
We found no significant difference in survival rates
between patients with and without intraoral lesion
recurrence (Log Rank = 0.020, P = 0.89).
Neck management
From the 64 patients with primary OMM, twenty-five
patients refused a neck dissection, including 22 patients
with clinically negative CLNM and three patients with
clinically suspicious positive CLNM. During the follow-
up period, five patients were lost, and late CLNM
occurred in three patients of the remaining 20 patients
(15%, 3/20).
The remaining thirty-nine patients with primary OMM
received a neck dissection, including 23 patients with
clinically positive CLNM and 16 patients with clinically
negative CLNM. Among the 16 patients with clinically
negative CLNM, pathological CLNM was confirmed in
13 patients (81.3%, 13/16). Our data showed that the rate
of CLNM in the group with neck dissection was signifi-
cantly higher than that in the group without neck dissec-
tion (c
2 = 15.8, P < 0.001). Among the 23 patients with
clinically positive CLNM, pathological CLNM was con-
firmed in all patients (100%, 23/23), with six patients
showing extra-capsular spread of lymph nodes. During
the follow-up period, seven patients were lost, with late
CLNM occurring in five of the remaining 32 patients
(15.6%, 5/32). The incidence of late CLNM was signifi-
cantly correlated with N staging (Z = -2.2, P = 0.027) and
the incidence of recurrence of the intraoral lesion (Z =
-2.1, P = 0.036). Furthermore, we found that the inci-
dence of late CLNM in patients with positive CLNM and
recurrence of the intraoral lesion was significantly higher
than those patients with negative CLNM and without
late recurrence of the intraoral lesion. In clinically
CLNM-negative patients, the incidence of late CLNM in
patients confirmed with pathological CLNM was signifi-
cantly higher than those without pathological CLNM
(Z = -2.7, P = 0.007). No significant relationship between
late CLNM and the lesion site (P = 0.79), T stage (P =
0.66), biopsy method (P = 0.65), intraoral lesion treat-
ment method (P = 0.93), neck dissection method (P =
0.34), extra-capsular spread (P = 0.25), post-operative
distant metastasis (P = 0.10) or post-operative che-
motherapy (P = 0.44) was found.
The mean survival period of patients with pathologi-
cally CLNM was 37.2 ± 5.3 (95% CI: 26.9-47.5) months
and this was shorter than that of those without CLNM
[49.0 ± 6.0 (95% CI: 37.3-60.7) months], although this
difference was not significant (Log Rank = 2.609, P =
0.106). However, if the status of CLNM was based on
clinical examination, the difference in survival period
between patients with and without CLNM was significant
(Log Rank = 8.08, P = 0.004), and the survival period of
patients with CLNM [29.8 ± 6.6 (95% CI: 16.9-42.7)
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[50.0 ± 4.9 (95% CI: 40.5-59.6) months]. The mean survi-
val period of patients with extra-capsular spread of
lymph nodes was 21.2 ± 5.1 (95% CI: 11.1-31.2) months,
which was shorter than that of those without extra-cap-
sular spread of lymph nodes [39.8 ± 5.7 (95% CI:
28.7-51.0) months]. However, this difference was not sig-
nificant (Log Rank = 0.383, P = 0.54). Late CLNM
occurred in eight patients, but the difference in survival
rate was not significant between patients with and with-
out late CLNM (Log Rank = 0.032, P = 0.86). In addition,
the difference in survival rate was not significant between
patients with and without neck dissection (Log Rank =
1.919, P = 0.166).
Distant metastasis
Two patients presenting with distant metastasis before
treatment died at the 6th and 15th month after surgical
treatment. The survival period of the patients without
distant metastasis was 43.7 ± 4.1 (95% CI: 35.6-51.7)
months, and the difference between these two groups of
patients was significant (Log Rank = 7.341, P = 0.007).
Post-operative distant metastasis occurred in 17
patients. The site of distant metastasis was lung only (10
patients), brain only (two patients) and multi-sites
including lung, brain, breast, liver and bones (five
patients). Figure 1 shows that the mean survival period
of the patients with post-operative distant metastasis
was 22.6 ± 4.7 (95% CI: 13.4-31.7) months, which was
significant shorter (Log Rank = 14.282, P < 0.001) than
that of those without post-operative distant metastasis
[53.4 ± 4.4 (95% CI: 44.8-61.9) months].
Clinical stage
Figure 2 shows that the mean survival period of patients
with clinical stage III disease was 55.9 ± 5.5 (95% CI: 45.2-
66.7) months, which was significantly longer than that of
those with clinical stage IV disease [34.8 ± 5.0 (95% CI:
25.1-44.5) months] (Log Rank = 7.245, P = 0.007).
Post-operative chemotherapy
Forty patients received post-operative chemotherapy.
Figure 3 shows that the mean survival period of patients
with post-operative chemotherapy was 47.8 ± 4.4 (95% CI:
39.2-56.4) months, which was significantly longer (Log
Rank = 6.639, P = 0.010) than that of those without post-
operative chemotherapy [19.0 ± 3.7 (95% CI: 11.8-26.2)
months]. The survival rate of patients with two to four
cycles of chemotherapy was 76.7% (23/30). While the sur-
vival rate of patients with one or more than four cycles of
chemotherapy was both 40%, the survival rate of those
without chemotherapy was 33.3% (4/12). Among the
patients without neck dissection, the mean survival period
of patients with post-operative chemotherapy was 53.8 ±
6.6 (95% CI: 40.8-66.9) months, which was longer than
that of those without post-operative chemotherapy [21.8 ±
5.3 (95% CI: 11.3-32.2) months], although this difference
was not significant (Log Rank = 3.249, P = 0.071). How-
ever, the post-operative chemotherapy could benefit the
patients (both with and without post-operative distant
metastasis) on the survival period (Log Rank = 4.927, P =
0.026) compared to the patients without post-operative
chemotherapy.
Post-operative radiotherapy
Post-operative radiotherapy was used in two patients in
whom the intraoral and neck lesions could not be con-
t r o l l e db ys u r g e r ya n dp o s t - operative chemotherapy.
These two patients died within the first year of follow-
up period.
Treatment protocol
Our study summarized four types of treatment proto-
cols. This consisted of intraoral lesion treatment only
(cryotherapy) (five cases), intraoral lesion treatment
(cryotherapy, surgery or both) with neck dissection
(14 cases), intraoral lesion treatment (cryotherapy or
cryotherapy with surgery) with chemotherapy (20 cases),
and intraoral treatment (cryotherapy, surgery or both)
with neck dissection and chemotherapy (25 cases). The
data showed a significant difference of survival rate
among these four treatment protocols (Log Rank =
8.445, df = 3, P = 0.038).
Recurrent OMM
Among the 14 patients with recurrent OMM, five
patients were diagnosed with intraoral lesion recurrence
(three hard palatal mucosa and two maxillary gingival
mucosa), and nine patients were diagnosed with
intraoral lesion recurrence and CLNM (four hard palatal
mucosa, three maxillary gingival mucosa and two man-
dibular gingival mucosa). Cryotherapy only, surgery only
and cryotherapy with surgery were performed in six, five
Table 2 Th treatment results between the primary intraoral lesion stage and treatment methods
Classification Treatment methods Case number Late intraoral recurrence Late cervical lymph node metastasis Late distant metastasis
T3 stage Cryotherapy 33 6/26 (23.1%) 5/26 (19.2%) 11/26 (42.3%)
Surgery 7 1/5 (20%) 0/5 0/5
Both 13 5/11 (45.5%) 1/11 (9.1%) 1/11 (9.1%)
T4a stage Cryotherapy 3 2/3 (66.7%) 2/3 (66.7%) 2/3 (66.7%)
Surgery 4 1/4 (25%) 0/4 3/4 (75%)
Both 4 1/3 (33.3%) 0/3 2/3 (66.7%)
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received a neck dissection while the remaining patient
with a recurrent intraoral lesion refused a neck dissec-
tion. Pathological CLNM was confirmed in 12 patients
(including all of the nine patients with intraoral lesion
recurrence and CLNM). No significant relationship was
found among the clinico-pathological parameters. Dur-
ing the follow-up period, one patient was lost while the
remaining 13 patients were followed-up from 10 to 67
months with a mean of 35.4 months. In these patients,
the overall survival rate of patients with recurrent
OMM was 38.5%, the intraoral lesion recurrent rate was
15.4%, and the incidence of late CLNM was 46.2%.
Discussion
At present, the cause of OMM remains unclear, and the
prognosis is still poor. The management of OMM remains
a big challenge. In our study, the survival period of
patients with clinical stage III disease was significantly
longer than those with clinical stage IV disease. For the
patients with primary OMM, the overall survival rate was
61.5%, and the 1-, 2-, 3- and 5-year survival rates were
58.3%, 53.1%, 35.0%, and 36.4%, respectively. From our
results, regardless of whether cryotherapy was used, we
recommend that radical surgery including wide intraoral
resection and neck dissection to be the first choice of
treatment.
Although chemotherapy is commonly used in the treat-
ment in malignancies, the therapeutic value of chemother-
apy on melanoma has not been previously reported [13].
Recently, chemotherapy has been used for OMM patients,
and many different types of chemotherapeutic agents have
been reported, such as DTIC, CDDP, Vincristine, Nimus-
tine, Temozolomide, Tamoxifen [14]. Combining che-
motherapeutic agents such as DTIC and CDDP has also
been reported [15-17]. In this study, a post-operative che-
motherapy protocol of DTIC with CDDP was implemen-
ted for patients with both primary and recurrent OMMs.
The survival period of patients with post-operative che-
motherapy was significantly longer than that of those
without post-operative chemotherapy. As such, the imple-
mentation of a post-operative chemotherapy protocol with
Figure 1 The mean survival period of the patients with post-operative distant metastasis was significant shorter than that of those
without post-operative distant metastasis (Kaplan-Meier analysis).
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for OMM patients. In addition, two to four cycles of post-
operative chemotherapy was found to improve survival
rates when compared to other cycle regimes. However,
further prospective studies are needed to confirm the effi-
cacy of post-operative chemotherapy in the treatment of
OMM.
Neck dissection is strongly recommended in OMM
patients with clinically positive CLNM [18], because
CLNM is significantly correlated with survival rate in the
OMM patients [19,20]. However, there is still some con-
troversy on the issue of neck dissection in the clinically
CLNM-negative patients. In our study, 16 clinically
CLNM-negative patients received neck dissection, and
81.3% of these patients were confirmed with pathological
CLNM. In contrast, among the 20 clinically CLNM-nega-
tive patients who did not receive a neck dissection,
pathological CLNM was confirmed in three patients
(15%). In these 36 clinically CLNM-negative patients, the
incidence of pathological CLNM was at least 44.4%. As
such, because of this high incidence, neck dissection is
recommended in OMM patients. As far as the type of
neck dissection method to be performed, functional neck
dissection should be performed in the clinically CLNM-
negative patients while radical neck dissection should be
performed in the clinically CLNM-positive patients.
The use of cryotherapy has been reported in the treat-
ment of cutaneous melanoma [21], but seldom reported
in the treatment of OMM [22]. In our study, cryotherapy
was used to treat intraoral lesions. Although the intraoral
lesion recurrence rate was not significant between the
various treatment methods of cryotherapy, surgery or
both, the intraoral lesion recurrence rate in patients with
cryotherapy was slightly higher than those who received
surgery. Based on our experience, either cryotherapy or
surgery alone is beneficial, in terms of the intraoral lesion
recurrence rate, in patients with T3 lesions or smaller-
sized lesions. Even though cryotherapy has been used as
Figure 2 The mean survival period of the patients at the clinical stage III was significantly longer than that of those at the clinical
stage IV (Kaplan-Meier analysis).
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recurrence of the intraoral lesion may occur. As such,
surgical resection should always be considered in these
cases to completely remove the intraoral lesion. For
patients with T4a lesions or even larger-sized T3
lesions, cryotherapy alone is not sufficient to control
the disease. Instead, surgical resection is strongly
recommended.
T h e r ei ss t i l ls o m ec o n t r o v e r s yo nt h eu s eo fp o s t -
operative radiotherapy in OMM patients. Previous stu-
dies have reported that the local control rate after surgery
and radiotherapy is higher than either surgery or radio-
therapy alone, although the difference in survival was not
significant [23,24]. Furthermore, mucosal melanoma is
usually regarded as a radiation-resistant tumor [25,26].
On the other hand, some authors have reported on the
benefits of radiotherapy alone in the treatment of muco-
sal melanoma [20,22,27-29]. In our study, post-operative
radiotherapy was not routinely used for OMM patients.
Although post-operative chemotherapy was implemented
in the majority of patients, the efficacy of concurrent
post-operative chemotherapy and radiotherapy in
improving the prognosis of OMM should be further
investigated in prospective trials.
Conclusions
OMM is a rare disease with a clinically poor prognosis.
Radical surgery including wide intraoral resection and
neck dissection is recommended as the primary treat-
ment modality. In addition, a post-operative chemother-
apy protocol of DTIC and CDDP may be beneficial in
the treatment both primary and recurrent OMMs.
Additional material
Additional file 1: AJCC-TNM classification for the mucosal
melanoma of the head and neck. This table contains detail information
of TNM classification for the mucosal melanoma of the head and neck
(in AJCC cancer staging manual, 7th Edition, published in 2010).
Additional file 2: Clinical data of 78 OMM patients. This table
contains detail information of each OMM patient including individual
information, symptoms, TNM staging, biopsy method, treatment protocol,
and prognosis.
Figure 3 The mean survival period of the patients with post-operative chemotherapy was significantly longer than that of those
without post-operative chemotherapy(Kaplan-Meier analysis).
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